Effect of lifetime antiepileptic drug treatment history on efficacy and tolerability of adjunctive brivaracetam in adults with focal seizures: Posthoc analysis of a randomized, placebo-controlled trial
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier BV in Epilepsy Research
- Vol. 167, 106369
- https://doi.org/10.1016/j.eplepsyres.2020.106369
Abstract
No abstract availableFunding Information
- UCB Pharma
This publication has 15 references indexed in Scilit:
- Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysisEpilepsy & Behavior, 2020
- Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic DrugsJAMA Neurology, 2018
- Time to onset of sustained ≥50% responder status in patients with focal (partial‐onset) seizures in three phase III studies of adjunctive brivaracetam treatmentEpilepsia, 2016
- Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studiesNeurology, 2016
- A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizuresEpilepsia, 2015
- Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trialEpilepsia, 2013
- Patterns of treatment response in newly diagnosed epilepsyNeurology, 2012
- Results of treatment changes in patients with apparently drug‐resistant chronic epilepsyAnnals of Neurology, 2007
- Likelihood of seizure remission in an adult population with refractory epilepsyAnnals of Neurology, 2007
- Diagnosing refractory epilepsy: response to sequential treatment schedulesEuropean Journal of Neurology, 2006